Bremelanotide in men with erectile dysfunction unresponsive to sildenafil
Positive clinical results occurred in 33.5% with bremelanotide versus 8.5% placebo; intercourse satisfaction was greater.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Men with erectile dysfunction who had not responded to sildenafil
n=342
Positive clinical results occurred in 33.5% with bremelanotide versus 8.5% placebo; intercourse satisfaction was greater.
Older intranasal formulation; current U.S. approval is subcutaneous and specifically not indicated for men.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Positive clinical results occurred in 33.5% with bremelanotide versus 8.5% placebo; intercourse satisfaction was greater.